AI Prior Art Search: The New “Pre-Deal” Weapon for Drug Patent Risk—Before You Pay
Most pharma and biotech teams don’t realize they’re making a high-stakes bet before they ever sign the term sheet.
They focus on the obvious: freedom-to-operate (FTO) ch…

Most teams treat formulation patents like a black box. That’s why they miss the design-around window.
In pharma, the “real” competitive advantage often isn’t the active ingredient—it’s the formulation. The release profile, stability, particle engineeri…

Russia’s latest VED/SSM listings aren’t just another regulatory update—they’re a live signal for when generics can (and can’t) enter the market.
If you’re a brand team, a generic manufacturer, or an investor underwriting pipeline timing, the real quest…

Pharma pipelines don’t fail because of science. They fail because of patents.
That’s the uncomfortable truth behind “Freedom to Operate” (FTO): it’s not a legal checkbox—it’s a business decision made under uncertainty.
If you’re building a launch plan,…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Competitive Advantage
Most pharma conversations about generics start and end with the ANDA. It’s familiar, it’s efficient, and it’s often the fastest route to market. But if you’re buildin…

Pharma IP teams: Russia’s patent-term extension rules just got harder to ignore. Here’s what to know right now.
If your company files in Russia—or relies on Russian exclusivity to protect revenue—this is the moment to stop treating patent-term extensio…

Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
In pharma, “good patents” are often treated like a finish line. File the application, secure the grant, move on.
But the market doesn’t reward paperwork—it…

Hospitals are sitting on a quiet, expensive blind spot: patent-expiration intelligence.
For years, the industry has treated “when a drug goes generic” as a legal milestone—something handled by counsel, tracked in spreadsheets, and revisited only when a…

Generic launches don’t “happen”—they arrive. And if you’re still waiting for the market to tell you when the next generic is coming, you’re already behind.
In pharma, timing is everything: formulary decisions, contracting leverage, inventory planning, …

Most people “search” the FDA Orange Book. The best people mine it.
If you’re in pharma BD, licensing, investing, or competitive intelligence, you already know the Orange Book is more than a regulatory database—it’s a map of where value is being created…